Lipocomb

Ezetimibe, the active ingredient in Lipocomb, is a combination lipid‑lowering agent presented as an oral tablet for oral use. It is indicated for the treatment of hypercholesterolaemia, mixed dyslipidaemia and familial hypercholesterolaemia in adults. GNH USA supplies Lipocomb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lipocomb is used to manage lipid disorders by targeting cholesterol synthesis and absorption pathways. - Hypercholesterolaemia: lowers low‑density lipoprotein (LDL‑C) and total cholesterol levels. - Mixed dyslipidaemia: reduces LDL‑C while modestly improving triglycerides and HDL‑C. - Familial hypercholesterolaemia: provides potent LDL‑C reduction in genetically elevated cholesterol states.

Lipocomb may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort after meals. - Diarrhoea: loose stools, usually transient. - Myalgia: muscle aches without weakness. - Elevated liver enzymes: mild transaminase increase. - Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with dark urine. - Acute liver injury: marked elevation of hepatic enzymes or jaundice. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Pancreatitis: sudden abdominal pain with vomiting.

Before initiating Lipocomb, consider the following safety measures. - Monitor liver function: obtain baseline and periodic ALT/AST tests. - Assess muscle symptoms: advise patients to report unexplained muscle pain or weakness. - Avoid use in pregnancy: contraindicated due to potential fetal harm. - Use caution in renal impairment: adjust monitoring frequency as needed. - Review concomitant medications: evaluate for potential drug‑drug interactions. - Store at ambient temperature: keep in the original pack, protect from moisture.

Lipocomb can interact with several medicines; careful review is required.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): may increase rosuvastatin exposure. - Gemfibrozil: markedly raises risk of myopathy and rhabdomyolysis. - Aluminum or magnesium antacids: can reduce ezetimibe absorption.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Niacin: potential for additive liver toxicity. - Other fibrates (except gemfibrozil): may increase muscle toxicity risk.